Objective The current staging system for esophageal adenocarcinoma only considers tumor
grade in early tumors. The aim of this study was to evaluate the impact of tumor …

Background Cancer staging systems are designed to predict survival and stratify patients.
The 7 th edition of the American Joint Commission on Cancer (AJCC7) staging system for …

Objective To determine the association between neoadjuvant chemotherapy and
chemoradiation therapy on completeness of pathologic response and to assess the impact …

Background Neoadjuvant chemoradiotherapy is the standard treatment for locally advanced
esophageal adenocarcinomas (EAC). Pathological response is thought to be a major …

Background Neoadjuvant treatment is standard for locally advanced esophageal cancer.
However, whether the addition of radiation to neoadjuvant regimen improves survival …

Background The 5-year survival for patients with esophageal carcinoma remains poor
despite neoadjuvant therapy and surgery. The eighth American Joint Committee on Cancer …

Background There is no consensus on the most effective modality for the treatment of
resectable esophageal adenocarcinomas (EAC). We theorized that treatment modality may …

Abstract Background and Objectives The gold standard for locoregional esophageal cancer
(LEC) treatment includes preoperative chemoradiation and surgical resection, with possible …

Objective: To determine the impact of histology on pathologic response, survival outcomes,
and recurrence patterns in patients with esophageal cancer (EC) who received neoadjuvant …

Complete response to neoadjuvant therapy, determined by pathologic examination of the
resection specimen (pCR), is associated with a favorable outcome in esophageal …